January 28, 2008 - Toshiba America Medical Systems Inc. said today the FDA cleared the new open-bore 1.5T Vantage Titan MR system, which will be commercially available in the first quarter of 2008.
The open-bore of the Vantage Titan is 18 percent larger than other 1.5T systems on the market, featuring a large 71-centimeter patient aperture.
Toshiba says the Titan’s large clinical field-of-view is unique for this bore size and produces high-quality images without compromising homogeneity or overall imaging performance. The system also features Toshiba’s patented Pianissimo noise reduction technology, which creates a better imaging experience for all patients.
The Vantage Titan MR system also uses Toshiba’s proprietary, contrast-free MRA techniques – fresh blood imaging (FBI), contrast-free improved angiography (CIA), time-spatial labeling inversion pulse (Time-SLIP), and time-slip angiography (TSA). Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD).
For more information: www.medical.toshiba.com
March 30, 2026 
